A detailed history of Virtu Financial LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Virtu Financial LLC holds 60,480 shares of TCRX stock, worth $68,947. This represents 0.01% of its overall portfolio holdings.

Number of Shares
60,480
Previous 11,388 431.09%
Holding current value
$68,947
Previous $17,000 547.06%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$1.45 - $1.92 $71,183 - $94,256
49,092 Added 431.09%
60,480 $110,000
Q2 2025

Aug 12, 2025

BUY
$1.1 - $1.8 $401 - $657
365 Added 3.31%
11,388 $17,000
Q1 2025

May 12, 2025

BUY
$1.35 - $3.12 $14,881 - $34,391
11,023 New
11,023 $15,000
Q4 2023

Feb 26, 2024

BUY
$2.66 - $6.76 $48,991 - $124,505
18,418 New
18,418 $107,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $21.6M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.